Predicting cost of inhalational anesthesia at low fresh gas flows: impact of a new generation carbon dioxide absorbent

Moody, Alastair E; Beutler, Bryce D.; Moody, Catriona E

doi:10.4103/2045-9912.285558

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global warming potential of desflurane, scaled by clinical potency, is approximately 40–50 times that of sevoflurane and isoflurane over a 100‐year period [10, 18]. Desflurane is also significantly more expensive than other volatiles [24].…”

Section: Background To Action Guidancementioning

confidence: 99%

Action guidance for addressing pollution from inhalational anaesthetics

et al. 2022

View full text Add to dashboard Cite

Summary Climate change is a real and accelerating existential danger. Urgent action is required to halt its progression, and everyone can contribute. Pollution mitigation represents an important opportunity for much needed leadership from the health community, addressing a threat that will directly and seriously impact the health and well‐being of current and future generations. Inhalational anaesthetics are a significant contributor to healthcare‐related greenhouse gas emissions and minimising their climate impact represents a meaningful and achievable intervention. A challenge exists in translating well‐established knowledge about inhalational anaesthetic pollution into practical action. CODA is a medical education and health promotion charity that aims to deliver climate action‐oriented recommendations, supported by useful resources and success stories. The CODA‐hosted platform is designed to maximise engagement of the global healthcare community and draws upon diverse experiences to develop global solutions and accelerate action. The action guidance for addressing pollution from inhalational anaesthetics is the subject of this article. These are practical, evidence‐based actions that can be undertaken to reduce the impact of pollution from inhalational anaesthetics, without compromising patient care and include: removal of desflurane from drug formularies; decommissioning central nitrous oxide piping; avoidance of nitrous oxide use; minimising fresh gas flows during anaesthesia; and prioritising total intravenous anaesthesia and regional anaesthesia when clinically safe to do so. Guidance on how to educate, implement, measure and review progress on these mitigation actions is provided, along with means to share successes and contribute to the essential, global transition towards environmentally sustainable anaesthesia.

show abstract

Section: Background To Action Guidancementioning

confidence: 99%

Action guidance for addressing pollution from inhalational anaesthetics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It should be emphasized that this study presumes that isoflurane is more cost-effective because it costs the least in liquid form and per MAC-hour at 0.5 L/m of FGF administration [ 30 ]. However, this deduction is controversial due to concerns that isoflurane use is associated with comparatively prolonged time to extubation during cases when anesthetic duration exceeds eight hours [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Knowledge Gaps in Anesthetic Gas Utilization in a Large Academic Hospital System: A Multicenter Survey

Shah

Przybysz

Wang

et al. 2023

Cureus

View full text Add to dashboard Cite

“…Isoflurane (ISO) is a kind of commonly gaseous anesthetic that is often used for sedation and anesthesia in neurosurgery. 18 As the widely used inhalation anesthetic, ISO has been widely recognized for its safety and neuroprotective effects. In short, short-term and low-concentration ISO therapy has a protective effect on ischemic brain tissue.…”

Section: Introductionmentioning

confidence: 99%

Current research progress of isoflurane in cerebral ischemia/reperfusion injury: a narrative review

Xue

Chen

et al. 2022

Med Gas Res

View full text Add to dashboard Cite

Cerebral ischemia/reperfusion injury is an important factor leading to poor prognosis in ischemic stroke patients. Therefore, it is particularly important to find effective remedial measures to promote the health of patients to return to society. Isoflurane is a safe and reliable anesthetic gas with a long history of clinical application. In recent years, its protection function to human body has been widely recognized, and nowadays isoflurane for cerebral protection has been widely studied, and the stable effect of isoflurane has satisfied many researchers. Basic studies have shown that isoflurane’s protection of brain tissue after ischemia/reperfusion involves a variety of signaling pathways and effector molecules. Even though many signaling pathways have been described, more and more studies focus on exploring their mechanisms of action, in order to provide strong evidence for clinical application. This could prompt the introduction of isoflurane therapy to clinical patients as soon as possible. In this paper, several confirmed signaling pathways will be reviewed to find possible strategies for clinical treatment.

show abstract

Predicting cost of inhalational anesthesia at low fresh gas flows: impact of a new generation carbon dioxide absorbent

Cited by 6 publications

References 20 publications

Action guidance for addressing pollution from inhalational anaesthetics

Action guidance for addressing pollution from inhalational anaesthetics

Knowledge Gaps in Anesthetic Gas Utilization in a Large Academic Hospital System: A Multicenter Survey

Current research progress of isoflurane in cerebral ischemia/reperfusion injury: a narrative review

Contact Info

Product

Resources

About